Nanoparticles could aid more effective lung cancer treatment

Published: 6-Mar-2015

Nanoparticles' selective drug release to human lung tumour tissue demonstrated for the first time


Use of nanoparticles as carriers for medicines has led to a significant increase in the effectiveness of current cancer medicines in lung tumour tissue.

Working in a joint project at the NIM (Nanosystems Initiative Munich) Excellence Cluster, scientists from the Helmholtz Zentrum München (HMGU) and the Ludwig-Maximilians-Universität (LMU) in Munich have developed nanocarriers that site-selectively release medicines/drugs at the tumor site in human and mouse lungs. The research is reported in the journal ACS Nano.1

The Munich scientists have developed nanocarriers that release the carried drugs only in lung tumour areas. The team headed by Silke Meiners, Oliver Eickelberg and Sabine van Rijt from the Comprehensive Pneumology Center (HMGU), working with colleagues from the Chemistry Department (LMU) headed by Thomas Bein, were able to show nanoparticles' selective drug release to human lung tumour tissue for the first time.

Tumour tissue in the lung contains high concentrations of certain proteases, which are enzymes that break down and cut specific proteins. The scientists took advantage of this by modifying the nanocarriers with a protective layer that only these proteases can break down, a process that then releases the drug. Protease concentrations in the healthy lung tissue are too low to cleave this protective layer and so the medicines stay protected in the nanocarrier.

'Using these nanocarriers we can very selectively release a drug such as a chemotherapeutic agent specifically at the lung tumour,' reports research group leader Meiners. 'We observed that the drug's effectiveness in the tumour tissue was 10 to 25 times greater compared with when the drugs were used on their own.

'At the same time, this approach also makes it possible to decrease the total dose of medicines and consequently to reduce undesirable effects.' Further studies will now be directed to examine the safety of the nanocarriers in vivo and verify the clinical efficacy in an advanced lung tumour mouse model.

Reference

1. van Rijt, S. et al. (2015): Protease Mediated Release of Chemotherapeutics From Mesoporous Silica Nanoparticles to Ex Vivo Human and Mouse Lung Tumors, ACS Nano. doi: 10.1021/nn5070343; http://pubs.acs.org/doi/abs/10.1021/nn5070343

You may also like